Literature DB >> 24766485

Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice.

Vanessa Legry1, Derrick M Van Rooyen2, Barbara Lambert1, Christine Sempoux3, Laurence Poekes1, Regina Español-Suñer1, Olivier Molendi-Coste1, Yves Horsmans1, Geoffrey C Farrell2, Isabelle A Leclercq1.   

Abstract

Non-alcoholic fatty liver (steatosis) and steatohepatitis [non-alcoholic steatohepatitis (NASH)] are hepatic complications of the metabolic syndrome. Endoplasmic reticulum (ER) stress is proposed as a crucial disease mechanism in obese and insulin-resistant animals (such as ob/ob mice) with simple steatosis, but its role in NASH remains controversial. We therefore evaluated the role of ER stress as a disease mechanism in foz/foz mice, which develop both the metabolic and histological features that mimic human NASH. We explored ER stress markers in the liver of foz/foz mice in response to a high-fat diet (HFD) at several time points. We then evaluated the effect of treatment with an ER stress inducer tunicamycin, or conversely with the ER protectant tauroursodeoxycholic acid (TUDCA), on the metabolic and hepatic features. foz/foz mice are obese, glucose intolerant and develop NASH characterized by steatosis, inflammation, ballooned hepatocytes and apoptosis from 6 weeks of HFD feeding. This was not associated with activation of the upstream unfolded protein response [phospho-eukaryotic initiation factor 2α (eIF2α), inositol-requiring enzyme 1α (IRE1α) activity and spliced X-box-binding protein 1 (Xbp1)]. Activation of c-Jun N-terminal kinase (JNK) and up-regulation of activating transcription factor-4 (Atf4) and CCAAT/enhancer-binding protein-homologous protein (Chop) transcripts were however compatible with a 'pathological' response to ER stress. We tested this by using intervention experiments. Induction of chronic ER stress failed to worsen obesity, glucose intolerance and NASH pathology in HFD-fed foz/foz mice. In addition, the ER protectant TUDCA, although reducing steatosis, failed to improve glucose intolerance, hepatic inflammation and apoptosis in HFD-fed foz/foz mice. These results show that signals driving hepatic inflammation, apoptosis and insulin resistance are independent of ER stress in obese diabetic mice with steatohepatitis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24766485     DOI: 10.1042/CS20140026

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

1.  Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.

Authors:  Weijun Wang; Jinfang Zhao; Wenfang Gui; Dan Sun; Haijiang Dai; Li Xiao; Huikuan Chu; Fan Du; Qingjing Zhu; Bernd Schnabl; Kai Huang; Ling Yang; Xiaohua Hou
Journal:  Br J Pharmacol       Date:  2018-01-03       Impact factor: 8.739

Review 2.  Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease.

Authors:  Frank T Spradley; Jillian A Smith; Barbara T Alexander; Christopher D Anderson
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-03-06       Impact factor: 4.310

3.  Glycolipid Metabolism Disorder in the Liver of Obese Mice Is Improved by TUDCA via the Restoration of Defective Hepatic Autophagy.

Authors:  Qinyue Guo; Qindong Shi; Huixia Li; Jiali Liu; Shufang Wu; Hongzhi Sun; Bo Zhou
Journal:  Int J Endocrinol       Date:  2015-11-19       Impact factor: 3.257

4.  Soybean Oil-Derived Poly-Unsaturated Fatty Acids Enhance Liver Damage in NAFLD Induced by Dietary Cholesterol.

Authors:  Janin Henkel; Eugenia Alfine; Juliana Saín; Korinna Jöhrens; Daniela Weber; José P Castro; Jeannette König; Christin Stuhlmann; Madita Vahrenbrink; Wenke Jonas; André Kleinridders; Gerhard P Püschel
Journal:  Nutrients       Date:  2018-09-18       Impact factor: 5.717

Review 5.  Macrophages, Low-Grade Inflammation, Insulin Resistance and Hyperinsulinemia: A Mutual Ambiguous Relationship in the Development of Metabolic Diseases.

Authors:  Gerhard Paul Püschel; Julia Klauder; Janin Henkel
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

Review 6.  Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies.

Authors:  Tingyu Fang; Hua Wang; Xiaoyue Pan; Peter J Little; Suowen Xu; Jianping Weng
Journal:  Int J Biol Sci       Date:  2022-09-06       Impact factor: 10.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.